July 1, 2025
Econs are actionable with another bang having resurrected!
Not a lot of action in the aftermarket followed by the pre-open
News: Mesoblast (MESO +$0.81 or +7.44% to $11.70 pre-open) announced alignment with the FDA on items required for filing a Biologics License Application (BLA) for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic heart failure with reduced ejection fraction (HFrEF) and inflammation. MESO intends to file by the end of the year for accelerated approval in patients with end-stage ischemic HFrEF implanted with an LVAD.
The last session of June is today and then markets will close at 1 p.m. on Thursday and remain shut on Friday for the 4th of July.
Never leave an investor uninformed …
I say what others won’t, so you can do what others can’t!
June 23, 2025
Escape, escape, run fast ... NO trust in this management team of connivers
6/20/25 - Back at it, The Harvard Apparatus RT (OTCQB: HRGN) the pump of share pricing is BACK in with 5475 shares trading up (+$0.14) after weekly session barely or the usual no shares trading. If I had to guess <usually right> today’s investor meeting did NOT meet expectation <as usual>. Post Thursday’s holiday, Wednesday’s share pricing $0.00 after Tuesday’s +$0.05 <+995 shares traded> and Monday’s $0.00). Back to my admonition, a Ponzi scheme!
6/4/25 ... Questions exist as stock dives in afternoon -$0.7141 to $0.93 with 5000 shares traded and suddenly is “resurrected” at the close to +$0.01 with 9,250 shares traded – PONZI Scheme at its best or was convicted Bernie Madoff also resurrected in DST Capital (run by HRGN’s President)???
No partner, No cash, NO runway, extensive liabilities and debts to past employee and university associations
July 3, 2025
Enjoy it while you can …
After a better-than-expected June jobs report amid multiple cross-currents; session closes to the upside
News: Moderna (MRNA +$0.21 or +0.69% to $30.49) stock popped after the Centers for Disease Control and Prevention recommended the RSV vaccine for at-risk adults in their 50s. Health Secretary Kennedy Jr. sided with the previous Advisory Committee on Immunization Practices which, in April, recommended MRNA's mResvia for adults ages 50 to 59 who have a high risk of developing severe respiratory syncytial virus, or RSV. The virus causes cold like symptoms in most people, but can be serious or deadly in older adults.
Thursday is a shortened trading session, with the NYSE and the Nasdaq closed at 1 p.m. ET. U.S. markets are closed on Friday for Independence Day
I say what others won’t, so you can do what others can’t!
Never leave an investor uninformed!
June 23, 2025
Escape, escape, run fast ... NO trust in this management team of connivers 6/20/25 - Back at it, The Harvard Apparatus RT (OTCQB: HRGN) the pump of share pricing is BACK in with 5475 shares trading up (+$0.14) after weekly session barely or the usual no shares trading. If I had to guess <usually right> today’s investor meeting did NOT meet expectation <as usual>. Post Thursday’s holiday, Wednesday’s share pricing $0.00 after Tuesday’s +$0.05 <+995 shares traded> and Monday’s $0.00). Back to my admonition, a Ponzi scheme! 6/4/25 ... Questions exist as stock dives in afternoon -$0.7141 to $0.93 with 5000 shares traded and suddenly is “resurrected” at the close to +$0.01 with 9,250 shares traded – PONZI Scheme at its best or was convicted Bernie Madoff also resurrected in DST Capital (run by HRGN’s President)??? No partner, No cash, NO runway, extensive liabilities and debts to past employee and university associations Harvard Apparatus RT (OTCQB: HRGN) Net loss of -$1.659 M or -$0.10 per share, revenue of $45 K, cash position of $1.728 M with a Q2/25 runway; accumulated deficit of -$101.3 M, liabilities of -$11.9 K in addition to -$207 K owed to former employees, and 161 K to Un of Pitt and Yale <No release, 8-K, filed 5/14>. What about past (still unpaid for months of work) consultants with documentation!! Going Concern status still in effect.
June 17, 2025
Gene therapy companies are riding a new waave ... Verve Therapeutics (VERV +$4.79 or +76.31 to $11.06) rallied after the gene editing company agreed to be acquired by Eli Lilly (LLY -$9.13 or -1.15% to $798.28) or $10.50 per share, a premium of 67.5% on the company’s last close. The deal, which is worth up to $1.3 billion, is expected to close in Q3/25. The 2 companies were already partnered on a handful of 1-time treatments for cardiovascular diseases. VERV's leading program would use gene editing to permanently turn off the PCSK9 gene. The gene makes a protein that, when elevated, leads to high cholesterol. LLY also agreed to pay an additional $3 per share in a contingent value right. Lilly will pay the CVR when the first patient receives Verve's leading drug in a U.S. P3 study for atherosclerotic cardiovascular disease.
May 13, 2025
SGMO is trading at $0.449 down -$0.2967 or -39.7% Cantor is acting as sole book-running manager for the offering.
July 3, 2025
RegMed Investors (RMi) Closing Bell: Happy 4th
July 3, 2025
RegMed Investors (RMi) Closing Bell: Feeling the high, just haven’t exhaled yet
July 1, 2025
RegMed Investors (RMi) Closing Bell: the wall of worry was scaled
July 1, 2025
RegMed Investors’ (RMi) pre-open: Are we ready for the 2nd half and resumption of the earnings cycle
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
